Clinical efficacy of different chemotherapy regimens for advanced non-small cell lung cancer and correlations between tumor markers and efficacy
ZHAO Cong1,HOU Dongdong1, and WANG Sheng2
1.Department of Oncology,Peking University Shougang Hospital, Beijing 100144,China; 2.Economic Management Section,General Hospital of Chinese People’s Armed Police Force, Beijing 100039,China
Abstract：Objective To investigate the clinical efficacy of different chemotherapy regimens in the treatment of advanced non-small cell lung cancer and the correlations between tumor markers and clinical efficacy.Methods Ninety-six cases of advanced non-small cell lung cancer patients admitted between January 2015 and June 2017 were selected as subjects. They were randomly divided into GP and AP group. GP group was given gemcitabine plus cisplatin chemotherapy, while AP group was given permedusa plus cisplatin chemotherapy. Chemotherapy efficacy and tumor markers were compared between the two groups.Results After chemotherapy, the ORR (29.17%) and DCR (81.25%) in the AP group were significantly higher than those in the GP group (P<0.05). After chemotherapy, the level of cancer embryo antigens in the GP group and AP group was 54.6±7.9 and 23.5±5.9 respectively, while CA125 was 87.8±7.2 and 50.4±8.3 respectively. Before treatment, CEA and CA125 levels of the two groups were not statistically significant, but were significantly different after treatment (P<0.05). After treatment, the index of the AP group was decreased more significantly than in GP group, and the difference was statistically significant (P<0.05).Conclusions AP chemotherapy can significantly improve the clinical efficacy of patients with advanced non-small cell lung cancer, and reduce the level of tumor markers. It is worth promoting.
赵聪, 侯东东, 王胜. 不同化疗方案治疗晚期非小细胞肺癌的临床疗效及肿瘤标志物与疗效的相关性[J]. 武警医学, 2018, 29(5): 504-506.
ZHAO Cong,HOU Dongdong, and WANG Sheng. Clinical efficacy of different chemotherapy regimens for advanced non-small cell lung cancer and correlations between tumor markers and efficacy. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(5): 504-506.
Bai M S, Wang X C, Luo L, et al. Clinical Efficacy of Aidi Injection Combined with DP Chemotherapy Regimen for Female Advanced Lung Cancer[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2016.
Kaderbhai C, Richard C, Fumet J D, et al. Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer[J]. Oncoimmunology, 2017, 6(9): 1339.
[10]
Matikas A, Ν. Kentepozidis, Ardavanis A, et al. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG)[J].Cancer Chemotherapy & Pharmacology, 2016, 78(2):1-8.
2018, Vol. 29 
